NCT01809600已完成不适用
Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Event-free survival
研究概览
简要总结
This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.
详细描述
Inclusion criteria
- pathologically confirmed BL or BL-U by World Health Organization 2008 criteria
- age >20 yrs
- received rituximab+chemotherapy as first-line treatment
- with measurable or evaluable lesion
- with complete set of clinical and laboratory data for the analysis
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •pathologically confirmed Burkitt's lymphoma (BL) or High grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL (BL-U) by WHO 2008 criteria
- •age >20 yrs
- •received rituximab+chemotherapy as first-line treatment
- •with measurable or evaluable lesion
排除标准
- •patients with BL or BL-U previously treated with rituximab
结局指标
主要结局
Event-free survival
时间窗: one year
Event-free survival is measured from the time from treatment initiation to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death)
次要结局
- complete response rate(1-year)
- overall survival(1-year)
- Grade 4 hematologic toxicities(one year)
研究者
Junshik Hong
Assistant Professor, Department of Internal Medicine
Gachon University Gil Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell LymphomaLymphoma, Mantle-CellNCT00992134St. Bortolo Hospital41
招募中
2 期
Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety StudyAdvanced Hepatocellular CarcinomaNCT06301399Tianjin Medical University Cancer Institute and Hospital20
已完成
3 期
Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic PolyangiitisMicroscopic Polyangiitis (MPA)NCT03920722Assistance Publique - Hôpitaux de Paris8
已完成
1 期
A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal EncephalitisRasmussen's EncephalitisChronic Focal EncephalitisNCT00259805California Pacific Medical Center Research Institute10
已完成
2 期
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 AutoantibodiesChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)NCT03864185Nagoya University25